Menu
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€44.94
-2.670%

Roche Bobois S.a.

WKN: A2JQRU / Name: Roche Bobois S.a. / Stock / ? /

?
-0.830%

Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

?
0.620%

Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

?
-1.320%

Roche Finance Europe B.v.

WKN: A3LEL7 / Name: Roche Finance Europe B.v. / Stock / ? /

€102.31
0.070%

Roche Finance Europe B.v.

WKN: A3LEL8 / Name: Roche Finance Europe B.v. / Stock / ? /

€101.78
0.070%

Roche Finance Europe B.v.

WKN: A3LRTS / Name: Roche Finance Europe B.v. / Stock / ? /

€101.67
0.000%

Roche Finance Europe B.v.

WKN: A3LRTT / Name: Roche Finance Europe B.v. / Stock / ? /

€101.66
0.160%

Roche Finance Europe B.v.

WKN: A3LX6K / Name: Roche Finance Europe B.v. / Stock / ? /

€102.62
0.030%

Roche Finance Europe B.v.

WKN: A3LX6L / Name: Roche Finance Europe B.v. / Stock / ? /

€95.64
0.160%

Roche Holdings Inc.

WKN: A3LVX8 / Name: Roche Holdings Inc. / Stock / ? /

€97.84
0.510%

Roche Holding AG

WKN: A424UK / Name: Roche Holding / Stock / ? /

€364.65
2.860%

FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, in combination

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche RHHBY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking label expansion of Enspryng (satralizumab) for the

Rochefocauld
Account activated